logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Aptose Biosciences Inc.

APS.TO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplā€¦ read more

Healthcare

Biotechnology

27 years

CAD

Exclusive to Premium users

Price

per share adjusted in CAD

$1.72

Price

0.00%

$0.00

$1.72

Previous Close

$1.71

Open

Premium

52w Discount
Market Cap

$4.390m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$21.333m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.11

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$7.393m

$7.467m

Assets

$14.860m

Liabilities

$8.983m

Debt
Debt to Assets

120.3%

-0.4x

Debt to EBITDA
Free Cash Flow

-$27.014m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
ā†‘ TopSummaryPriceFinancials
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.